PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 71974

Title: How has the disease course of pediatric ulcerative colitis changed throughout the biologics era? A comparison with the IBSEN study

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 00503545

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Director, Doctor

Reviewer’s Country/Territory: Japan

Author’s Country/Territory: South Korea

Manuscript submission date: 2021-09-28

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-09-29 23:42

Reviewer performed review: 2021-10-10 13:57

Review time: 10 Days and 14 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>Grade A: Excellent</th>
<th>Grade B: Very good</th>
<th>Grade C: Good</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ]</td>
<td>[ Y ]</td>
<td></td>
</tr>
<tr>
<td>Language quality</td>
<td>Grade A: Priority publishing</td>
<td>Grade B: Minor language polishing</td>
<td>Grade C: A great deal of language polishing</td>
</tr>
<tr>
<td></td>
<td>[ ]</td>
<td>[ Y ]</td>
<td>[ ]</td>
</tr>
<tr>
<td>Conclusion</td>
<td>Accept (High priority)</td>
<td>Accept (General priority)</td>
<td>Minor revision</td>
</tr>
<tr>
<td></td>
<td>[ ]</td>
<td>[ Y ]</td>
<td>[ ]</td>
</tr>
<tr>
<td>Re-review</td>
<td>Yes</td>
<td>No</td>
<td></td>
</tr>
</tbody>
</table>
SPECIFIC COMMENTS TO AUTHORS

In this paper, the authors compare the clinical course of UC before and after the introduction of biological agents, and concluded that the incidence of relapse has decreased and the steroid-free period has increased after the introduction of the biological agent. This paper is well written and the results are clinically interesting. I only suggest the followings items which might strengthen the work.

1. If possible, please show the proportions of steroid-dependent and steroid-refractory patients in both Group A and Group B in Table1.

2. Please show the percentages of patients taking biologics other than infliximab in Group B after 2 and 5 years of treatment.
Name of journal: *World Journal of Gastroenterology*

**Manuscript NO:** 71974

**Title:** How has the disease course of pediatric ulcerative colitis changed throughout the biologics era? A comparison with the IBSEN study

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer’s code:** 05755618

**Position:** Peer Reviewer

**Academic degree:** FACP, MD

**Professional title:** Doctor

**Reviewer’s Country/Territory:** Japan

**Author’s Country/Territory:** South Korea

**Manuscript submission date:** 2021-09-28

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-10-11 04:16

**Reviewer performed review:** 2021-10-14 05:22

**Review time:** 3 Days and 1 Hour

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[ ] Grade B: Very good</th>
<th>[ Y] Grade C: Good</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade D: Fair</td>
<td>[ ] Grade E: Do not publish</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Language quality</th>
<th>[ ] Grade A: Priority publishing</th>
<th>[ Y] Grade B: Minor language polishing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Conclusion</th>
<th>[ ] Accept (High priority)</th>
<th>[ ] Accept (General priority)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Minor revision</td>
<td>[ Y] Major revision</td>
</tr>
</tbody>
</table>

| Re-review | [ Y] Yes | [ ] No |
SPECIFIC COMMENTS TO AUTHORS
In this article, the authors describe the IFX-effect on the Korean pediatric cohorts with ulcerative colitis. It is an interesting study. It may be worth publishing. However, there are some concerns before publishing the article. 1. The authors describe the comparison of the IBSEN study. However, the details of the IBSEM study have not been well described in the sentences. 2. The endoscopic procedure has not been described. Any AEs during the procedure? 3. The definition of remission is critical in this study. Would you explain the reason for excluding MES1 as a remission? If so, did you take biopsy samples? Did they achieve histological healing (= Geboes grade 0–1)? 4. Fig4 has too many graphics that are confusing for readers. Please reconstruct each figure according to before and after the approval of IFX treatment.
RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: *World Journal of Gastroenterology*

Manuscript NO: 71974

Title: How has the disease course of pediatric ulcerative colitis changed throughout the biologics era? A comparison with the IBSEN study

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 05755618

Position: Peer Reviewer

Academic degree: FACP, MD

Professional title: Doctor

Reviewer’s Country/Territory: Japan

Author’s Country/Territory: South Korea

Manuscript submission date: 2021-09-28

Reviewer chosen by: Jin-Lei Wang

Reviewer accepted review: 2022-01-05 12:16

Reviewer performed review: 2022-01-05 13:19

Review time: 1 Hour

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[Y] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
<th>[ ] Grade D: Fair</th>
<th>[ ] Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>[ ] Grade A: Priority publishing</td>
<td>[Y] Grade B: Minor language polishing</td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>[ ] Accept (High priority)</td>
<td>[Y] Accept (General priority)</td>
<td>[ ] Minor revision</td>
<td>[ ] Major revision</td>
<td>[ ] Rejection</td>
</tr>
<tr>
<td>Peer-reviewer</td>
<td>Peer-Review: [Y] Anonymous</td>
<td>[ ] Onymous</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SPECIFIC COMMENTS TO AUTHORS
The authors responded to the reviewers’ comments correctly, and the article was revised well. No further comments are available.
RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Gastroenterology
Manuscript NO: 71974
Title: How has the disease course of pediatric ulcerative colitis changed throughout the biologics era? A comparison with the IBSEN study
Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed
Peer-review model: Single blind
Reviewer’s code: 00503545
Position: Editorial Board
Academic degree: MD, PhD
Professional title: Director, Doctor
Reviewer’s Country/Territory: Japan
Author’s Country/Territory: South Korea
Manuscript submission date: 2021-09-28
Reviewer chosen by: Jin-Lei Wang
Reviewer accepted review: 2022-01-06 03:42
Reviewer performed review: 2022-01-07 06:31
Review time: 1 Day and 2 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[Y] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
<th>[ ] Grade D: Fair</th>
<th>[ ] Grade E: Do not publish</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Language quality</th>
<th>[Y] Grade A: Priority publishing</th>
<th>[ ] Grade B: Minor language polishing</th>
<th>[ ] Grade C: A great deal of language polishing</th>
<th>[ ] Grade D: Rejection</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Conclusion</th>
<th>[ ] Accept (High priority)</th>
<th>[Y] Accept (General priority)</th>
<th>[ ] Minor revision</th>
<th>[ ] Major revision</th>
<th>[ ] Rejection</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Peer-reviewer</th>
<th>Peer-Review: [Y] Anonymous</th>
<th>[ ] Onymous</th>
</tr>
</thead>
</table>
SPECIFIC COMMENTS TO AUTHORS
The manuscript including Table 2 has been significantly improved in the revised version. I have one thing to point out in the revised paper. The percentage of the steroid dependent patients in group A is 38.1% (8/21), and thus, please correct the percentage of the steroid dependent patients in group A from 48.1% to 38.1%.